Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

This study is currently recruiting participants. (see Contacts and Locations)

Verified August 2016 by Bristol-Myers Squibb

Sponsor:

Collaborators:

ICON Clinical Research

PPD

Molecular MD

MultiPharma

Q2 solutions

Donald E. Morisky

MD Anderson Symptom Inventory (MDASI-CML)

OBiS, Inc

Steering Committee

Information provided by (Responsible Party):

Bristol-Myers Squibb

ClinicalTrials.gov Identifier:

NCT01593254

First received: May 4, 2012

Last updated: September 23, 2016

Last verified: August 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	January 2022
Estimated Primary Completion Date:	January 2022 (Final data collection date for primary outcome measure)